Anthrax toxin is a critical virulence factor of Bacillus anthracis. The toxin comprises protective antigen (PA) and two enzymatic moieties, edema factor (EF) and lethal factor (LF), forming bipartite lethal toxin (LT) and edema toxin (ET). PA binds cellular surface receptors and is required for intracellular translocation of the enzymatic moieties. For this reason, anti-PA antibodies have been developed as therapeutics for prophylaxis and treatment of human anthrax infection. Assays described publicly for the control of anti-PA antibody potency quantify inhibition of LT-mediated cell death or the ET-induced increase in c-AMP levels. These assays do not fully reflect and/or capture the pathological functions of anthrax toxin in humans. Herein, we report the development of a cell-based gene reporter potency assay for anti-PA antibodies based on the rapid LT-induced degradation of c-Jun protein, a pathogenic effect that occurs in human cells. This new assay was developed by transducing Hepa1c1c7 cells with an AP-1 reporter lentiviral construct and has been qualified for specificity, accuracy, repeatability, intermediate precision, and linearity. This assay not only serves as a bioassay for LT activity, but has applications for characterization and quality control of anti-PA therapeutic antibodies or other products that target the AP-1 signaling pathway.

2010-01-01·Biologie Aujourd'hui

Intérêt des anticorps recombinants dans la protection médicale contre les agents du bioterrorisme : l'exemple de la maladie du charbon

Review

作者: Pelat, Thibault ; Vidal, Dominique ; Thullier, Philippe ; Paucod, Jean-Charles

Recombinant antibodies are a highly successful class of therapeutic molecules, they are well adapted for use against bio-weapons (BW) as they act immediately, are often synergistic with other therapeutic molecules, have a long half-life and are well tolerated. Anthrax is regarded at high risk of being used as BW, and its pathogenic properties depend on toxins, which might be neutralized by antibodies. These toxins are made of three different types of sub-units (PA, LF, EF). Several anti-PA have been developed, including an original approach by our team. We have developed an anti-LF, as recommended by experts. Our anti-PA antibody, and to a lesser extend our anti-LF antibody, will be presented here.

2003-01-01·Clinical & Experimental Metastasis3区 · 医学

Effects of alpha-difluoromethylornithine on local recurrence and pulmonary metastasis from MDA-MB-435 breast cancer xenografts in nude mice.

3区 · 医学

Article

作者: John F. Harms ; Danny R. Welch ; Laura Craig ; Sharlene Washington ; Lindsay J. Texter ; Andrea Manni ; Laurence M. Demers ; James W. Griffith ; Michael F. Verderame ; Michael Cloud ; David Mauger

We have recently shown that administration of alpha-difluoromethylornithine (DFMO), an irreversible inhibitor of ornithine decarboxylase (ODC), the first and rate-limiting enzyme in polyamine (PA) biosynthesis reduces pulmonary metastasis from MDA-MB-435 breast cancer xenografts in nude mice. The present experiments were designed to further explore PA involvement in breast cancer metastasis, using GFP-tagged MDA-MB-435 cells that can be tracked at the single cell level. Administration of DFMO significantly reduced the number of mice with pulmonary metastasis as well as the number of metastases per mouse. Both single-cell and multicellular metastatic deposits were similarly suppressed, thus suggesting that DFMO was inhibiting lung colonization by tumor cells rather than preventing progression of single-cell deposits to overt metastasis. DFMO administration also significantly reduced local recurrences following removal of the primary tumor. Prolongation of DFMO treatment to 14 weeks did not yield a superior antimetastatic effect beyond that provided by a 10-week course of therapy. Discontinuation of DFMO, on the other hand, was associated with local regrowth of the tumors and, possibly, recurrence of pulmonary metastasis. These data provide a rationale for testing the efficacy of anti-PA treatment within the context of adjuvant therapy of breast cancer.

100 项与 Anthraxumab 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
炭疽	临床1期	荷兰	IQ Therapeutics BV	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ISC2022	N/A	缺血性卒中	-	Blank-NPA	憲遞繭鹽範觸構憲顧窪(製壓壓鬱網糧積襯網築) = 膚餘鹹選鏇艱製鹹窪顧膚壓廠醖艱願觸鏇顧糧 (簾觸醖遞餘廠廠願艱壓 ) 更多	-	2022-02-01
				NG-NPA	憲遞繭鹽範觸構憲顧窪(製壓壓鬱網糧積襯網築) = 餘獵鑰選醖選醖夢夢簾膚壓廠醖艱願觸鏇顧糧 (簾觸醖遞餘廠廠願艱壓 ) 更多
ASCO_GI2019	N/A	肝细胞癌	-	DAA therapy	(膚窪膚製觸網膚壓膚鹽) = 膚鹹獵鑰壓築艱鏇衊積膚選範餘衊夢鏇築膚繭 (鹽衊醖醖範艱鏇淵膚構, 39.5 ~ not reached) 更多	积极	2019-01-29
				No DAA therapy	(膚窪膚製觸網膚壓膚鹽) = 襯鬱壓艱簾膚網觸蓋築膚選範餘衊夢鏇築膚繭 (鹽衊醖醖範艱鏇淵膚構, 9.8 ~ 14.5)